{"entity":{"id":"tscan","kind":"company","name":"TScan Therapeutics","aka":[],"tldr":"TCR discovery company that cut 75% of staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours (PRAME, MAGE-A4).","summary":"TScan Therapeutics, based in Waltham, Massachusetts, and listed as TCRX, is a TCR discovery company that cut 75 percent of its staff in September 2026 to focus on in vivo-engineered TCR-T for solid tumours against PRAME and MAGE-A4. It paused the phase 3 ALLOHA-2 trial of TSC-101 for lack of capital, has two in vivo TCR-T candidates entering IND-enabling studies with phase 1 planned for the fourth quarter of 2027, and previously ran a multiplexed autologous TCR-T basket study in solid tumours. OnCo links it to TCR-T cell therapy and in vivo CAR-T, to MAGE-A4 as a target, and to the idea of antibodies that see mutant KRAS and p53 fragments displayed on the cell surface. Whether a company can survive the gap between pausing a phase 3 and dosing a new first-in-human candidate is the open question its reorganisation raises. The TCR-T technology page carries the field.","asOf":"2026-09-04","links":[{"label":"Strategic reorganisation","url":"https://www.biospace.com/press-releases/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors"}],"tags":["pivot"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["tcr-t","in-vivo-car-t"],"targets":["mage-a4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Waltham, MA","country":"US","companyType":"cell-therapy","website":"https://www.tscan.com","ticker":"TCRX","investors":[],"funding":[]},"route":"/companies/tscan/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/"}],"idea":[{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/"}]}}